Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access open-label study of RO5185426 in metastatic melanoma
2010-023526-21Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Roche. Primary endpoint: Safety and tolerability. Started Dec 2010; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-023526-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023526-21.